Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Accounts Payables (2019 - 2025)

Nurix Therapeutics (NRIX) has disclosed Accounts Payables for 7 consecutive years, with $11.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Accounts Payables fell 2.33% to $11.2 million in Q4 2025 year-over-year; TTM through Nov 2025 was $11.2 million, a 2.33% decrease, with the full-year FY2025 number at $11.2 million, down 2.33% from a year prior.
  • Accounts Payables was $11.2 million for Q4 2025 at Nurix Therapeutics, up from $8.6 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $11.5 million in Q4 2024 to a low of $2.2 million in Q3 2023.
  • A 5-year average of $6.0 million and a median of $5.9 million in 2024 define the central range for Accounts Payables.
  • Peak YoY movement for Accounts Payables: tumbled 63.87% in 2023, then skyrocketed 119.73% in 2025.
  • Nurix Therapeutics' Accounts Payables stood at $6.6 million in 2021, then fell by 23.85% to $5.1 million in 2022, then rose by 26.4% to $6.4 million in 2023, then soared by 79.38% to $11.5 million in 2024, then decreased by 2.33% to $11.2 million in 2025.
  • Per Business Quant, the three most recent readings for NRIX's Accounts Payables are $11.2 million (Q4 2025), $8.6 million (Q3 2025), and $6.0 million (Q2 2025).